siRNA Therapies

Sunday, November 10, 2024

10:30 AM – 11:45 AM MST

Location: Sonoran Sky Ballroom 4

Moderator(s)

NM

Nitin Mehrotra, Phd

Head of Pharmacometrics
Alnylam Pharmaceuticals

Speaker(s)

Jeff Kearns, PhD (he/him/his)

Director, Translational Modeling & Simulation
Novartis
Cambridge, Massachusetts, United States
Vivaswath Ayyar, PhD

Associate Scientific Director
J&J Innovative Medicine
Philadelphia, Pennsylvania, United States
NM

Nitin Mehrotra, Phd

Head of Pharmacometrics
Alnylam Pharmaceuticals

Disclosure(s):

Nitin Mehrotra, Phd: Alnylam: Employment (Ongoing), Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (Ongoing); Takeda: Employment (Ongoing), Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (Ongoing)

Jeff Kearns, PhD: Novartis: Employment (Ongoing), Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (Ongoing); Sanofi: Employment (Ongoing); SK Life Science: Employment (Terminated, August 16, 2024)

Vivaswath S. Ayyar, PhD: J&J: Employment (Ongoing), Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (Ongoing)

Presentations:

10:30 AM – 10:55 AM MST

First, Best, or Next in class? Applying forward and reverse translation approaches to accelerate siRNA projects from discovery to FIH.
Speaker: Jeff Kearns, PhD (he/him/his) – Novartis
10:55 AM – 11:20 AM MST

Quantitative Pharmacology Principles and Model-Informed Development Approaches for RNAi Therapeutics
Speaker: Vivaswath S. Ayyar, PhD – J&J Innovative Medicine
11:20 AM – 11:45 AM MST

Innovating the landscape: Is MIDD of siRNA unique?
Speaker: Nitin Mehrotra, Phd – Alnylam Pharmaceuticals